Telomeres and cancer: A tale with many endings

Current Opinion in Genetics and Development

Volumn 13, Issue 1, 2003, Pages 70-76

  Blasco, María A ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE; TELOMERASE INHIBITOR;

CANCER; CANCER CELL; CARCINOGENESIS; CELL DIVISION; CHROMOSOME; CHROMOSOME ABERRATION; DNA DAMAGE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENOTOXICITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TELOMERE;

EID: 0037309155     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(02)00011-4     Document Type: Review

References (57)

1. Blackburn E.H. Switching and signaling at the telomere. Cell. 106:2001;661-673.
2. Chan S.W.L., Blackburn E.H. New ways not to make ends meet: telomerase, DNA damage proteins and heterochromation. Oncogene. 21:2002;553-563.
3. De Lange T. Protection of mammalian telomeres. Oncogene. 21:2002;532-540.
4. Griffith J.D., Comeau L., Rosenfield S., Stansel R.M., Bianchi A., Moss H., de Lange T. Mammalian telomeres end in a large duplex loop. Cell. 97:1999;503-514.
5. Goytisolo F.A., Blasco M.A. Many ways to telomere dysfunction: in vivo studies using mouse models. Oncogene. 21:2002;584-591.
6. Espejel S., Franco S., Rodríguez-Perales S., Bouffler S.D., Cigudosa J.C., Blasco M.A. Mammalian Ku86 mediates chromosomal fusions and apoptosis caused by critically short telomeres. EMBO J. 21:2002;2207-2219.
7. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature. 31:1990;458-460.
8. Collins K., Mitchell J.R. Telomerase in the human organism. Oncogene. 21:2002;564-579.
9. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., Wright W.E. Extension of life-span by introduction of telomerase into normal human cells. Science. 279:1998;349-352.
10. Serrano M., Blasco M.A. Putting the stress on senescence. Curr. Opin. Cell Biol. 13:2001;748-753.
11. Blasco M.A., Lee H.-W., Hande P., Samper E., Lansdorp P., DePinho R., Greider C.W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 91:1997;25-34.
12. Lee H.W., Blasco M.A., Gottlieb G.J., Horner J.W., Greider C.W., DePinho R.A. Essential role of mouse telomerase in highly proliferative organs. Nature. 392:1998;569-574.
13. Herrera E., Samper E., Martín-Caballero J., Flores J.M., Lee H.-W., Blasco M.A. Disease states associated to telomerase deficiency appear earlier in mice with short telomeres. EMBO J. 18:1999;2950-2960.
14. -/- mice with short telomeres. EMBO Rep. 2:2001;800-807 In this paper, we demonstrate that it is possible to elongate short telomeres in the context of the telomerase-deficient mouse by re-introducing telomerase. Rescue of the population of short telomeres prevents chromosome fusions and loss of viability in these mice. These findings encourage the use of telomerase in the therapy of age-related diseases or premature aging syndromes that are characterized by critical telomere shortening.
15. •].
16. Hiyama E., Hiyama K. Clinical utility of telomerase in cancer. Oncogene. 21:2001;643-649.
17. Chin L., Artandi S.E., Shen Q., Tam A., Lee S.L., Gottlieb G.J., Greider C.W., DePinho R.A. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell. 97:1999;527-538.
18. González-Suárez E., Samper E., Flores J.M., Blasco M.A. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat. Genet. 26:2000;114-117.
19. Artandi S.E., Chang S., Lee S.L., Alson S., Gottlieb G.J., Chin L., DePinho R.A. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature. 406:2000;641-645.
20. Rudolph K.L., Millard M., Bosenberg M.W., DePinho R.A. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat. Genet. 28:2001;155-159.
21. Greenberg R.A., Chin L., Femino A., Lee K.H., Gottlieb G.J., Singer R.H., Greider C.W., DePinho R.A. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell. 97:1999;515-525.
22. Smogorzewska A., de Lange T. Different telomere damage signaling pathways in human and mouse cells. EMBO J. 21:2002;4338-4348 This elegant paper dissects the tumor suppressor pathways that mediate telomere dysfunction in mouse and human cells. Whereas in the mouse p53 is the main mediator of telomere dysfunction, both p53 and Rb/p16 pathways are important in human cells.
23. van Steensel B., Smogorzewska A., de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell. 92:1998;401-413.
24. Samper E., Goytisolo F., Slijepcevic P., van Buul P., Blasco M.A. Mammalian Ku86 prevents telomeric fusions independently of the length of TTAGGG repeats and the G-strand overhang. EMBO Rep. 1:2000;244-252.
25. Goytisolo F., Samper E., Edmonson S., Taccioli G.E., Blasco M.A. Absence of DNA-PKcs in mice results in anaphase bridges and in increased telomeric fusions with normal telomere length and G-strand overhang. Mol. Cell Biol. 21:2001;3642-3651.
26. Gilley D., Tanaka H., Hande M.P., Kurimasa A., Li G.C., Oshimura M., Chen D.J. DNA-PKcs is critical for telomere capping. Proc. Natl. Acad. Sci. U.S.A. 98:2001;15084-15088.
27. cs in telomere capping. The paper shows that abrogation of either activity results in end-to-end fusions preferentially involving telomeres produced by leading-strand synthesis. The authors argue that these telomere-binding proteins could have a role in the post-replicative processing of telomeres.
28. Espejel S., Blasco M.A. Identification of telomere-dependent 'senescence-like' arrest in mouse embryonic fibroblasts. Exp. Cell Res. 276:2001;242-248 The senescence-like arrest shown by MEFs in culture is not likely to be mediated by telomere loss because MEFs have telomerase activity and very long telomeres. In this paper, we demonstrate that it is possible to trigger a telomere-mediated senescence-like arrest in MEFs by either short telomeres in the absence of telomerase (telomerase-deficient mice) or by deletion of the telomere-binding protein Ku86 (Ku86-deficient mice). Hence, telomere dysfunction produced by either short telomeres or altered telomere capping leads to senescence-like arrest in mouse cells.
29. Vogel H., Lim D.S., Karsenty G., Finegold M., Hasty P. Deletion of Ku86 causes early onset of senescence in mice. Proc. Natl. Acad. Sci. U.S.A. 96:1999;10770-10775.
30. Difilippantonio M.J., Zhu J., Chen H.T., Meffre E., Nussenzweig M.C., Max E.E., Ried T., Nussenzweig A. DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature. 404:2000;510-514.
31. Karlseder J., Smogorzewska A., de Lange T. Senescence induced by altered telomere state, not telomere loss. Science. 295:2002;2446-2449 The paper shows that altering the telomere state using a dominant negative mutant of the telomere-binding protein TRF2, it is possible to alter the average length at which telomeres trigger senescence in human cells. Therefore, by altering the telomere state it is possible to induce senescence.
32. Karlseder J., Broccoli D., Dai Y., Hardy S., de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science. 283:1999;1321-1325.
33. cs is important in the processing and signaling of a short telomere as damaged DNA.
34. Wang S., Guo M., Ouyang H., Li X., Cordon-Cardo C., Kurimasa A., Chen D.J., Fuks Z., Ling C.C., Li G.C. The catalytic subunit of DNA-dependent protein kinase selectively regulates p53-dependent apoptosis but not cell-cycle arrest. Proc. Natl. Acad. Sci. U.S.A. 97:2000;1584-1588.
35. Jimenez G.S., Bryntesson F., Torres-Arzayus M.I., Priestley A., Beeche M., Saito S., Sakaguchi K., Appella E., Jeggo P.A., Taccioli G.E.et al. DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage. Nature. 400:1999;81-83.
36. Smogorzewska A., van Steensel B., Bianchi A., Oelmann S., Schaefer M.R., Schnapp G., de Lange T. Control of human telomere length by TRF1 and TRF2. Mol. Cell Biol. 20:2000;1659-1668.
37. Ancelin K., Brunori M., Bauwens S., Koering C.E., Brun C., Ricoul M., Pommier J.P., Sabatier L., Gilson E. Targeting assay to study the cis functions of human telomeric proteins: evidence for inhibition of telomerase by TRF1 and for activation of telomere degradation by TRF2. Mol. Cell Biol. 22:2002;3474-3487 The authors elegantly dissect the roles of TRF1 and TRF2 by tagging these proteins to the telomeres. They show that TRF1 interferes with telomerase-dependent telomere elongation, and that TRF2, however seems to promote telomere degradation by unknown mechanisms.
38. Blasco M.A., Rizen M., Greider C.W., Hanahan D. Differential regulation of telomerase activity and its RNA component during multistage tumorigenesis. Nat. Genet. 12:1996;200-204.
39. Broccoli D., Godley L.A., Donehower L.A., Varmus H.E., de Lange T. Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol. Cell Biol. 16:1996;3765-3772.
40. Gonzalez-Suarez E., Samper E., Ramirez A., Flores J.M., Martin-Caballero J., Jorcano J.L., Blasco M.A. Increased epidermal tumors and increased wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 20:2001;2619-2630.
41. González-Suárez E., Flores J.M., Blasco M.A. Cooperation between p53 mutation and high telomerase transgenic expression in spontaneous cancer development. Mol. Cell Biol. 22:2002;7291-7301 This paper is a continuation of a previous work in which we showed that constitutive transgenic telomerase expression increased the frequency of carcinogen-induced tumors in mice [40]. This implied that telomerase could have a role in promoting tumorigenesis independently of telomere length. In this paper, we demonstrate that constitutive telomerase expression also increases spontaneous tumorigenesis with age. In addition, the authors generate a new mouse model with constitutive telomerase expression in the context of p53 deficiency. These double mutant mice show an increased frequency of spontaneous tumors at young ages, suggesting cooperation between telomerase activity and p53 mutation in accelerating tumorigenesis.
42. •], suggest that telomerase has a role in promoting tumorigenesis even if telomeres are sufficiently long, such as in the context of telomerase-transgenic mice.
43. Oh H., Taffet G.E., Youker K.A., Entman M.L., Overbeek P.A., Michael L.H., Schneider M.D. Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10308-11033.
44. Mattson M.P., Fu W., Zhang P. Emerging roles for telomerase in regulating cell differentiation and survival: a neuroscientist's perspective. Mech. Aging Dev. 122:2001;659-671.
45. Blasco M.A. Telomerase beyond telomeres. Nat. Rev. Cancer. 2:2002;627-633.
46. Nautiyal S., DeRisi J.L., Blackburn E.H. The genome-wide expression response to telomerase deletion in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U.S.A. 99:2002;9316-9321 This paper compares genome-wide gene expression changes in yeast containing telomerase activity versus yeast where telomerase is deleted. The fact that many genes show expression changes as a consequence of abrogation of telomerase also supports the notion that telomerase may impact processes other than telomere length maintenance.
47. Goytisolo F., Samper E., Martín-Caballero J., Finnon P., Herrera E., Flores J.M., Bouffler S.D., Blasco M.A. Short telomeres result in organismal hypersensitivity to ionizing radiation in mammals. J. Exp. Med. 192:2000;1625-1636.
48. Wong K.K., Chang S., Weiler S.R., Ganesan S., Chaudhuri J., Zhu C., Artandi S.E., Rudolph K.L., Gottlieb G.J., Chin L.et al. Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat. Genet. 26:2000;85-88.
49. McIlrath J., Bouffler S.D., Samper E., Cuthbert A., Wojcik A., Szumiel I., Bryant P.E., Riches A.C., Thompson A., Blasco M.A.et al. Telomere length abnormalities in mammalian radiosensitive cells. Cancer Res. 61:2001;912-915.
50. Lee K.H., Rudolph K.L., Ju Y.J., Greenberg R.A., Cannizzaro L., Chin L., Weiler S.R., DePinho R.A.et al. Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc. Natl. Acad. Sci. U.S.A. 98:2001;3381-3386.
51. Finnon P., Wong H.P., Silver A.R., Slijepcevic P., Bouffler S.D. Long but dysfunctional telomeres correlate with chromosomal radiosensitivity in a mouse AML cell line. Int. J. Radiat. Biol. 77:2001;1151-1162.
52. Franco S., Segura I., Riese H.H., Blasco M.A. Decreased B16F10 melanoma growth and impaired vascularization in telomerase-deficient mice with critically short telomeres. Cancer Res. 62:2002;552-559.
53. Corey D.R. Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene. 21:2002;631-637.
54. Damm K., Hemmann U., Garin-Chesa P., Hauel N., Kauffmann I., Priepke H., Niestroj C., Daiber C., Enenkel B., Guilliard B.et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 20:2001;6958-6968.
55. Hahn W.C., Stewart S.A., Brooks M.W., York S.G., Eaton E., Kurachi A., Beijersbergen R.L., Knoll J.H., Meyerson M., Weinberg R.A. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 5:1999;1164-1170.
56. Sachsinger J., Gonzalez-Suarez E., Samper E., Heicappell R., Muller M., Blasco M.A. Telomerase inhibition in RenCa, a murine tumor cell line with short telomeres, by overexpression of a dominant negative mTERT mutant, reveals fundamental differences in telomerase regulation between human and murine cells. Cancer Res. 61:1999;5580-5586.
57. Henson J.D., Neumann A.A., Yeager T.R., Reddel R.R. Alternative lengthening of telomeres in mammalian cells. Oncogene. 21:2002;598-610.